Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

Fig. 1

Flow chart of ToxNav® tested patients. Note: There were missing observations in the dose variable; Reduced initial dose was defined as less than 80% dose at first chemotherapy cycle; The proportion of reduced initial dose in the No-ToxNax cohort was added in the Figure for comparison purposes

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us